Dual-Inhibition of Human N-Myristoyltransferase Subtypes Halts Common Cold Pathogenesis: Atomistic Perspectives from the Case of IMP-1088.
IMP-1088
common cold
human N-myristoyltransferase
molecular dynamics simulation
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
15
09
2021
accepted:
21
12
2021
pubmed:
23
12
2021
medline:
19
2
2022
entrez:
22
12
2021
Statut:
ppublish
Résumé
The pharmacological inhibition of human N-myristoyltransferase (HsNMT) has emerged as an efficient strategy to completely prevent the replication process of rhinoviruses, a potential treatment for the common cold. This was corroborated by the recent discovery of compound IMP-1088, a novel inhibitor that demonstrated a dual-inhibitory activity against the two HsNMT subtypes 1 and 2 without inducing cytotoxicity. However, the molecular and structural basis for the dual-inhibitory potential of IMP-1088 has not been investigated. As such, we employ molecular modelling techniques to resolve the structural mechanisms that account for the dual-inhibitory prowess of IMP-1088. Sequence and nanosecond-based analyses identified Tyr296, Phe190, Tyr420, Leu453, Gln496, Val181, Leu474, Glu182, and Asn246 as residues common within the binding pockets of both HsNMT1 and HsNMT2 subtypes whose consistent interactions with IMP-1088 underpin the basis for its dual inhibitory potency. Nano-second-based assessment of interaction dynamics revealed that Tyr296 consistently elicited high-affinity π-π stacked interaction with IMP-1088, thus further highlighting its cruciality corroborating previous report. An exploration of resulting structural changes upon IMP-1088 binding further revealed a characteristic impeding of residue fluctuations, structural compactness, and a consequential burial of crucial hydrophobic residues, features required for HsNMT1/2 functionality. Findings present essential structural perspectives that augment previous experimental efforts and could also advance drug development for treating respiratory tract infections, especially those mediated by rhinoviruses.
Identifiants
pubmed: 34936193
doi: 10.1002/cbdv.202100748
doi:
Substances chimiques
Acyltransferases
EC 2.3.-
glycylpeptide N-tetradecanoyltransferase
EC 2.3.1.97
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e202100748Subventions
Organisme : Tshwane University of Technology
Organisme : The Center of High-Performance Computing
Informations de copyright
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
Références
G. Hayward, M. J. Thompson, R. Perera, C. B. Del Mar, P. P. Glasziou, C. J. Heneghan, ‘Corticosteroids for the common cold’, Cochrane Database Syst. Rev. 2015, 10, CD008116.
M. Thomas, P. A. Bomar, ‘Upper Respiratory Tract Infection’, Treasure Island (FL), 2021.
Y. Liu, Y. Zhang, W. Zhao, X. Liu, F. Hu, B. Dong, ‘Pharmacotherapy of Lower Respiratory Tract Infections in Elderly - Focused on Antibiotics’, Front. Pharmacol. 2019, 10, 1237.
J. H. Whitman, ‘Upper respiratory tract infections’, Clin. Fam. Prac. 2004, 6, 35-40.
A. L. Hersh, M. A. Jackson, L. A. Hicks, ‘Principles of Judicious Antibiotic Prescribing for Upper Respiratory Tract Infections in Pediatrics’, Pediatrics 2013, 132, 1146-54.
D. Blaas, R. Fuchs, ‘Mechanism of human rhinovirus infections’, Mol. Cell. Pediatr. 2016, 3, 21.
T. Heikkinen, A. Järvinen, ‘The common cold’, Lancet 2003, 361, 51-59.
C. Mirabelli, E. Scheers, J. Neyts, ‘Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis’, F1000Research 2017, 6, 1860.
A. Mousnier, A. S. Bell, D. P. Swieboda, J. Morales-Sanfrutos, I. Pérez-Dorado, J. A. Brannigan, J. Newman, M. Ritzefeld, J. A. Hutton, A. Guedán, A. S. Asfor, S. W. Robinson, I. Hopkins-Navratilova, A. J. Wilkinson, S. L. Johnston, R. J. Leatherbarrow, T. J. Tuthill, R. Solari, E. W. Tate, ‘Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus’, Nat. Chem. 2018, 10, 599-606.
M. J. Mäkelä, T. Puhakka, O. Ruuskanen, M. Leinonen, P. Saikku, M. Kimpimäki, S. Blomqvist, T. Hyypiä, P. Arstila, ‘Viruses and bacteria in the etiology of the common cold’, J. Clin. Microbiol. 1998, 36, 539-542.
H. M. van der Schaar, P. Leyssen, H. J. Thibaut, A. de Palma, L. van der Linden, K. H. W. Lanke, C. Lacroix, E. Verbeken, K. Conrath, A. M. Macleod, D. R. Mitchell, N. J. Palmer, H. van de Poël, M. Andrews, J. Neyts, F. J. M. van Kuppeveld, ‘A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor PI4KIIIβ’, Antimicrob. Agents Chemother. 2013, 57, 4971-81.
H. J. Thibaut, A. M. De Palma, J. Neyts, ‘Combating enterovirus replication: State-of-the-art on antiviral research’, Biochem. Pharmacol. 2012, 83, 185-92.
P. Jiang, Y. Liu, H.-C. Ma, A. V. Paul, E. Wimmer, ‘Picornavirus Morphogenesis’, Microbiol. Mol. Biol. Rev. 2014, 78, 418-37.
Y. Liu, M. G. Hill, T. Klose, Z. Chen, K. Watters, Y. A. Bochkov, W. Jiang, A. C. Palmenberg, M. G. Rossmann, ‘Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma’, Proc. Nat. Acad. Sci. 2016, 113, 8997-9002.
N. Moscufo, J. Simons, M. Chow, ‘Myristoylation is important at multiple stages in poliovirus assembly.’, J. Virol. 1991, 65, 2372-2380.
M. H. Wright, W. P. Heal, D. J. Mann, E. W. Tate, ‘Protein myristoylation in health and disease’, J. Chem. Biol. 2010, 3, 19-35.
A. S. Bell, J. E. Mills, G. P. Williams, J. A. Brannigan, A. J. Wilkinson, T. Parkinson, R. J. Leatherbarrow, E. W. Tate, A. A. Holder, D. F. Smith, ‘Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs’, PLoS Neglected Trop. Dis. 2012, 6, e1625.
D. Marc, M. Girard, S. Van Der Werf, ‘A Gly1to Ala substitution in poliovirus capsid protein VP0 blocks its myristoylation and prevents viral assembly’, J. Gen. Virol. 1991, 72, 1151-1157.
D. Marc, G. Masson, M. Girard, S. van der Werf, ‘Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles’, J. Virol. 1990, 64, 4099-4107.
D. Marc, G. Drugeon, A. Haenni, M. Girard, S. van der Werf, ‘Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence’, EMBO J. 1989, 8, 2661-2668.
I. Corbic Ramljak, J. Stanger, A. Real-Hohn, D. Dreier, L. Wimmer, M. Redlberger-Fritz, W. Fischl, K. Klingel, M. D. Mihovilovic, D. Blaas, H. Kowalski, ‘Cellular N-Myristoyltransferases Play a Crucial Picornavirus Genus-Specific Role in Viral Assembly, Virion Maturation, and Infectivity’, PLoS Pathog. 2018, 14, e1007203.
G. M. Lee, C. S. Craik, ‘Trapping moving targets with small molecules’, Science 2009, 324, 213-215.
J. A. Wells, C. L. McClendon, ‘Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.’, Nature 2007, 450, 1001-1009.
V. Hornak, C. Simmerling, ‘Targeting structural flexibility in HIV-1 protease inhibitor binding’, Drug Discovery Today 2007, 12, 132-138.
H. J. Dyson, P. E. Wright, ‘Intrinsically unstructured proteins and their functions.’, Nat. Rev. Mol. Cell Biol. 2005, 6, 197-208.
V. N. Uversky, C. J. Oldfield, A. K. Dunker, ‘Intrinsically Disordered Proteins in Human Diseases: Introducing the D2 Concept’, Annu. Rev. Biophys. 2008, 37, 215-246.
H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, ‘The Protein Data Bank’, Nucl. Ac. Res. 2000, 28, 235.
E. Thinon, R. A. Serwa, M. Broncel, J. A. Brannigan, U. Brassat, M. H. Wright, W. P. Heal, A. J. Wilkinson, D. J. Mann, E. W. Tate, ‘Global profiling of co- and post-translationally N-myristoylated proteomes in human cells’, Nat. Commun. 2014, 5, 4919.
V. Goncalves, J. A. Brannigan, E. Thinon, T. O. Olaleye, R. Serwa, S. Lanzarone, A. J. Wilkinson, E. W. Tate, R. J. Leatherbarrow, ‘A fluorescence-based assay for N-myristoyltransferase activity’, Anal. Biochem. 2012, 421, 342-344.
R. Salomon-Ferrer, A. W. Gotz, D. Poole, S. Le Grand, R. C. Walker, ‘Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald’, J. Chem. Theory Comput. 2013, 9, 3878-3888.
D. Case, H. Aktulga, K. Belfon, I. Ben-Shalom, S. Brozell, D. Cerutti, T. Cheatham, V. Cruzeiro, III, T. Darden, R. Duke, D. Ghoreishi, M. Gilson, H. Gohlke, A. Goetz, D. Greene, R. Harris, N. Homeyer, S. Izadi, A. Kovalenko, T. Kurtzman, T. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, D. Mermelstein, K. Merz, Y. Miao, G. Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, J. Shen, C. Simmerling, J. Smith, R. Salomon-Ferrer, J. Swails, R. Walker, J. Wang, H. Wei, R. Wolf, X. Wu, L. Xiao, D. York, P. Kollman, ‘AMBER 2020’, University of California, San Francisco 2020.
F. A. Olotu, C. Agoni, E. Adeniji, M. Abdullahi, M. E. Soliman, ‘Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins’, Appl. Biochem. Biotechnol. 2018, 187, 1061-1080.
S. Oguntade, P. Ramharack, M. E. Soliman, ‘Characterizing the ligand-binding landscape of Zika NS3 helicase-promising lead compounds as potential inhibitors’, Future Virol. 2017, 12, 261-273.
C. Agoni, P. Ramharack, M. E. S. Soliman, ‘Synergistic Interplay of The Co-administration of Rifampin and Newly Developed Anti-TB Drug: Could It Be a Promising New Line of TB Therapy?’, Comb. Chem. High Throughput Screening 2018, 21, 453-460.
C. Agoni, P. Ramharack, M. Soliman, ‘Co-inhibition as a strategic therapeutic approach to overcome rifampin resistance in tuberculosis therapy: atomistic insights’, Future Med. Chem. 2018, 10, 1665-1675.
D. R. Roe, T. E. Cheatham, ‘PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data’, J. Chem. Theory Comput. 2013, 9, 3084-3095.
E. Seifert, ‘OriginPro 9.1: Scientific data analysis and graphing software - Software review’, J. Chem. Inf. Model. 2014, 54, 1552.
E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, ‘UCSF Chimera - A Visualization System for Exploratory Research and Analysis’, J. Comput. Chem. 2004, 25, 1605-1612.
I. Massova, P. A. Kollman, ‘Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding’, Perspect. Drug Discov. Des. 2000, 18, 113-135.
P. A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, O. Donini, P. Cieplak, D. A. Case, T. E. Cheatham, ‘Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models’, Acc. Chem. Res. 2000, 33, 889-897.
B. R. Miller, T. D. McGee, J. M. Swails, N. Homeyer, H. Gohlke, A. E. Roitberg, ‘MMPBSA.py: An efficient program for end-state free energy calculations’, J. Chem. Theory Comput. 2012, 8, 3314-3321.
K. Huang, S. Luo, Y. Cong, S. Zhong, J. Z. H. Zhang, L. Duan, ‘An accurate free energy estimator: based on MM/PBSA combined with interaction entropy for protein-ligand binding affinity’, Nanoscale 2020, 12, 10737-10750.
T. Hou, J. Wang, Y. Li, W. Wang, T. Houa, J. Wangb, Y. Lia, W. Wang, ‘Assessing the performance of the MM/PBSA and MM/GBSA methods: I. The accuracy of binding free energy calculations based on molecular dynamics simulations’, J. Chem. Inf. Comput. Sci. 2011, 51, 69-82.
D. S. Biovia, ‘Discovery Studio’ 2017.
J. W. Shriver, S. P. Edmondson, ‘Ligand-binding interactions and stability.’, Methods Mol. Biol. 2009, 490, 135-164.
M. van den Noort, M. de Boer, B. Poolman, ‘Stability of Ligand-induced Protein Conformation Influences Affinity in Maltose-binding Protein’, J. Mol. Biol. 2021, 433, 167036.
L. Fusani, D. S. Palmer, D. O. Somers, I. D. Wall, ‘Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics’, J. Chem. Inf. Model. 2020, 60, 1528-1539.
A. H. Rabbad, C. Agoni, F. A. Olotu, M. E. Soliman, ‘Microbes, not humans: exploring the molecular basis of Pseudouridimycin selectivity towards bacterial and not human RNA polymerase’, Biotechnol. Lett. 2019, 41, 115-128.
C. Agoni, E. Y. Salifu, G. Munsamy, F. A. Olotu, M. Soliman, ‘CF3-Pyridinyl Substitution on Antimalarial Therapeutics: Probing Differential Ligand Binding and Dynamical Inhibitory Effects of a Novel Triazolopyrimidine-Based Inhibitor on Plasmodium falciparum Dihydroorotate Dehydrogenase’, Chem. Biodiversity 2019, 16, e1900365.
H. Washah, C. Agoni, F. A. Olotu, G. Munsamy, M. E. S. Soliman, ‘Tweaking α-galactoceramides: Probing the dynamical mechanisms of improved recognition for invariant natural killer T-cell receptor in cancer immunotherapeutics’, Curr. Pharm. Biotechnol. 2019, 21, 1354-1367.
F. Badichi Akher, A. Farrokhzadeh, F. A. Olotu, C. Agoni, M. E. S. Soliman, ‘The irony of chirality-unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[:B]thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFR4’, Org. Biomol. Chem. 2019, 17, 1176-1190.
T. Hou, J. Wang, Y. Li, W. Wang, ‘Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations’, J. Chem. Inf. Model. 2011, 51, 69-82.
H. Sun, L. Duan, F. Chen, H. Liu, Z. Wang, P. Pan, F. Zhu, J. Z. H. Zhang, T. Hou, ‘Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches’, Phys. Chem. Chem. Phys. 2018, 20, 14450-14460.
T. R. Weikl, B. Hemmateenejad, ‘How conformational changes can affect catalysis, inhibition and drug resistance of enzymes with induced-fit binding mechanism such as the HIV-1 protease’, Biochim. Biophys. Acta Proteins Proteomics 2013, 1834, 867-873.
D. E. Koshland, ‘Conformational changes: How small is big enough?’, Nat. Med. 1998, 4, 1112-1114.
D. E. Koshland, ‘Correlation of Structure an Function in Enzyme Action’, Science 1963, 142, 1533-1541.